Short answer
ArriVent BioPharma, Inc. (AVBP) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $5M with net income of −$40M.
Q3 2026 key financials · XBRL
- Revenue
- $5M
- Net income
- −$40M
- −15.3% YoY · +19.2% QoQ
- Operating margin
- -867.5%
- EPS (diluted)
- −$0.81
- −6.6% YoY · +22.9% QoQ
Source: XBRL data from the ArriVent BioPharma, Inc. (AVBP) Q3 2026 10-Q on SEC EDGAR. USD.
ArriVent BioPharma, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Collaboration revenue $5.0M, versus $0 in Q3 2025, from ARR-002 upfront payment
- Operating loss $43.4M vs $38.3M YoY, net loss $40.3M vs $35.0M
- R&D expense $38.9M vs $32.2M, early-stage programs increased $5.1M
- Cash, equivalents and short-term investments $393.2M; operating cash used $122.2M
- FURVENT failed its primary endpoint; existing liquidity expected to fund operations through at least twelve months
Risk Factors
- USPTO ex parte reexamination of RE ’687 Patent, initiated July 2026, could narrow or cancel claims
- RE ’687 Patent prosecution closed October 19, 2026, with certificate intended to confirm claims
- Patent validity disputes could eliminate protection for current and future product candidates
- Patent litigation could divert management and scientific resources and increase defense costs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ArriVent BioPharma, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.